Document is current
Any future updates will be listed below
-
Authors
Griffin, Timothy M.
Komaravolu, Ravi K.
Lopes, Erika Barboza Prado
Mehta-D’souza, Padmaja
Conner, Taylor
Kovats, Tessa
Kovats, Susan
Allen, Madeline
Harris, Peyton
Humphrey, Mary Beth
Welhaven, Hope D.
Brahmachary, Priyanka
June, Ronald K.
-
Funding
Funding for this research was provided by:
National Institutes of Health (R03AR066828, R01AR073964, R01AR081489, R03AR066828, R01AR073964, R01AR081489)
U.S. Department of Veterans Affairs (I01BX004666, I01BX004882)
Oklahoma Medical Research Foundation
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 13 January 2025
First Online: 18 January 2025
Declarations
:
: TM Griffin: Patent application pending entitled, “COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS USING A CD14 INHIBITOR” (#18/411,242); consulting – Novo Nordisk. P Brahmachary: Owns stock in OpenBioWorks. RK June: Owns stock in Beartooth Biotech and OpenBioWorks. No other authors report competing interests.
: All animals were housed and handled under veterinary oversight in the animal facility at the Oklahoma Medical Research Foundation (OMRF). All procedures were conducted following protocols approved by the AAALAC-accredited Institutional Animal Care and Use Committees at OMRF (protocol 12–47, 14–19, 17–24, 19–49, and 22–60) and Oklahoma City VA (protocol 1907-001).
